884654-08-4

Upstream product

• 3963-62-0 2,2-Diphenylethylamine 
• 5451-40-1 2,6-dichloropurine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 5451-40-1 2,6 dichloropurine 
• 557-21-1 zinc(II) cyanide 
• 264608-14-2 2-chloro-N-(2,2-diphenylethyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 

Downstream Products

• 884654-09-5 (1S,4R)-4-[2-chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-cyclopent-2-enol 
• 1001416-67-6 {(R)-1-[6-(2,2-diphenyl-ethylamino)-9H-purin-2-yl]-pyrrolidin-3-yl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Development of a scaleable process for the synthesis of the A2a agonist, UK-371,104

The development and utilization of a scaleable process for the manufacture of the A2a agonist UK-371,104 (1) is described. Key steps in the synthesis include (i) a palladium-catalyzed cyanation reaction to prepare the nitrile 10, (ii) a telescoped convers

PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof.and their preparation and use as A2A receptor agonists

ORGANIC COMPOUNDS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein Rl, R2 and R3 are as defined herein.

PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor,